LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

Search

Erasca Inc

Closed

1.6 3.23

Overview

Share price change

24h

Current

Min

1.51

Max

1.6

Key metrics

By Trading Economics

Income

-2.9M

-34M

Profit margin

-768.16

Employees

103

EBITDA

-2.5M

-38M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+109.68% upside

Dividends

By Dow Jones

Next Earnings

10 Nov 2025

Market Stats

By TradingEconomics

Market Cap

26M

445M

Previous open

-1.63

Previous close

1.6

Technical Score

By Trading Central

Confidence

Bearish Evidence

Erasca Inc Chart

Past performance is not a reliable indicator of future results.

Related News

9 Sept 2025, 23:37 UTC

Hot Stocks

Stocks to Watch: Oracle, Wearable Devices, GameStop

9 Sept 2025, 20:41 UTC

Earnings

Oracle's Backlog Surges With Major Customer Deals in 1Q

9 Sept 2025, 20:30 UTC

Earnings

GameStop 2Q Sales, Profit Rise

9 Sept 2025, 23:19 UTC

Market Talk

ANZ Adds a Further 50 Bps in FOMC Cuts to Outlook -- Market Talk

9 Sept 2025, 21:35 UTC

Earnings

Oracle Stock Soars on Strong AI Backlog. Earnings Were Good Enough. -- Barrons.com

9 Sept 2025, 21:32 UTC

Earnings

Oracle's Backlog Swells With Big Customer Deals -- Update

9 Sept 2025, 21:02 UTC

Acquisitions, Mergers, Takeovers

DHL Adds to Healthcare Logistics Services With Acquisition -- Update

9 Sept 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 Sept 2025, 20:33 UTC

Earnings

These Stocks Moved the Most Today: Apple, UnitedHealth, Nebius, Wolfspeed, Tourmaline Bio, Albemarle, Dell, and More -- Barrons.com

9 Sept 2025, 20:26 UTC

Earnings

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9 Sept 2025, 20:23 UTC

Earnings

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9 Sept 2025, 20:12 UTC

Earnings

Oracle Stock Jumps on Mixed Earnings Report -- Barrons.com

9 Sept 2025, 20:10 UTC

Earnings

Oracle Expects Cloud Infrastructure Rev to Grow 77% to $18 B This Fiscal Yr >ORCL

9 Sept 2025, 20:10 UTC

Earnings

Oracle Expects to Sign-Up Several Additional Multi-B-dollar Customers and RPO Is Likely to Exceed Half-A-Trillion Dollars Over Next Few Mos

9 Sept 2025, 20:09 UTC

Earnings

Synopsys Sees 4Q Adj EPS $2.76-Adj EPS $2.80 >SNPS

9 Sept 2025, 20:09 UTC

Earnings

Synopsys Sees 4Q Loss/Shr 16c-Loss 27c >SNPS

9 Sept 2025, 20:08 UTC

Earnings

Oracle 1Q Short-term Deferred Rev Were $12.1 B >ORCL

9 Sept 2025, 20:08 UTC

Earnings

Oracle 1Q Operating Income Was $4.3 B >ORCL

9 Sept 2025, 20:08 UTC

Earnings

Oracle Expects MultiCloud Rev to Grow Substantially Every Qtr for Several Years >ORCL

9 Sept 2025, 20:08 UTC

Earnings

Synopsys Sees 4Q Rev $2.23B-$2.26B >SNPS

9 Sept 2025, 20:07 UTC

Earnings

Oracle Total Remaining Performance Obligations Up to $455 B >ORCL

9 Sept 2025, 20:06 UTC

Earnings

Oracle 1Q Software Revenue $5.72B >ORCL

9 Sept 2025, 20:06 UTC

Earnings

Synopsys 3Q Adj EPS $3.39 >SNPS

9 Sept 2025, 20:06 UTC

Earnings

Oracle 1Q Cloud Revenue $7.19B >ORCL

9 Sept 2025, 20:05 UTC

Earnings

Oracle 1Q Rev $14.93B >ORCL

9 Sept 2025, 20:05 UTC

Earnings

Oracle 1Q EPS $1.01 >ORCL

9 Sept 2025, 20:05 UTC

Earnings

Synopsys 3Q EPS $1.50 >SNPS

9 Sept 2025, 20:05 UTC

Earnings

Oracle 1Q Services Revenue $1.35B >ORCL

9 Sept 2025, 20:05 UTC

Earnings

Oracle 1Q Adj EPS $1.47 >ORCL

9 Sept 2025, 20:05 UTC

Earnings

Oracle 1Q Hardware Revenue $670M >ORCL

Peer Comparison

Price change

Erasca Inc Forecast

Price Target

By TipRanks

109.68% upside

12 Months Forecast

Average 3.25 USD  109.68%

High 6 USD

Low 1 USD

Based on 4 Wall Street analysts offering 12 month price targets forErasca Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

4 ratings

2

Buy

1

Hold

1

Sell

Technical Score

By Trading Central

1.39 / 1.44Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

Very Strong Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
help-icon Live chat